http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113230405-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6875 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2021-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113230405-B |
| titleOfInvention | Application of reagent for inhibiting protein kinase CLK activity in preparation of medicine for treating or improving esophageal squamous cell carcinoma |
| abstract | The invention discloses the application of a reagent for inhibiting the activity of protein kinase CLK in the preparation of medicines for treating or improving esophageal squamous cell carcinoma, and relates to the technical field of tumor detection. The present invention finds out that The activity of protein kinase CLK is abnormally increased in ESCC patients, and by inhibiting the activity of CLK, the purpose of effective treatment or improvement of ESCC can be achieved, which provides a new way for the treatment and mechanism research of ESCC. |
| priorityDate | 2021-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.